The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation

Abstract

BRCA1-BARD1 constitutes a heterodimeric RING finger complex associated through its N-terminal regions. Here we demonstrate that the BRCA1-BARD1 heterodimeric RING finger complex contains significant ubiquitin ligase activity that can be disrupted by a breast cancer-derived RING finger mutation in BRCA1. Whereas individually BRCA1 and BARD1 have very low ubiquitin ligase activities in vitro, BRCA1 combined with BARD1 exhibits dramatically higher activity. Bacterially purified RING finger domains comprising residues 1-304 of BRCA1 and residues 25-189 of BARD1 are capable of polymerizing ubiquitin. The steady-state level of transfected BRCA1 in vivo was increased by co-transfection of BARD1, and reciprocally that of transfected BARD1 was increased by BRCA1 in a dose-dependent manner. The breast cancer-derived BARD1-interaction-deficient mutant, BRCA1 C61G , does not exhibit ubiquitin ligase activity in vitro. These results suggest that the BRCA1-BARD1 complex contains a ubiquitin ligase activity that is important in prevention of breast and ovarian cancer development.Germline mutations of BRCA1 predispose women to breast and ovarian cancers (1). BRCA1 contains several domains that interact with a variety of molecules and is potentially responsible for multiple functions in DNA damage repair, transcription, and cell-cycle regulation (2-4). BARD1 was identified in a yeast two-hybrid screen as a protein that interacts with BRCA1 (5). Both BRCA1 and BARD1 proteins contain a RING finger (5) and exist as homodimers or preferentially form stable heterodimers (6). The heterodimeric interaction is mediated by the flanking regions of the RING finger motif of the two molecules (6). Although a transcriptional function in the C terminus of BRCA1 has been recently reported (3), the biochemical function of the heterodimeric RING finger constituted from the N termini of BRCA1 and BARD1 is not known.Previously, we and others identified a highly conserved small RING finger protein, ROC1 (also called Rbx1 and Hrt1), as an essential subunit of the SCF Ub 1 ligase (7-10). The Ub ligase (E3) catalyzes the formation of polyubiquitin chains onto substrate proteins via isopeptide bonds utilizing the Ubs that have been sequentially activated by enzymes E1 and E2. Polyubiquitinated substrates are then rapidly degraded by the 26 S proteasome (11). The SCF and the APC are the two major Ub ligase complexes that regulate ubiquitin-mediated proteolysis during G 1 /S and anaphase (12), and contain the small RING finger proteins ROC1 and APC11, respectively (7-10). Point mutations in the RING finger domain of ROC1 completely disrupted the Ub ligase activity, suggesting an essential role of the domain for its activity (7). APC11 also contains Ub ligase activity in vitro (7). More recently, several large RING finger proteins, such as MDM2, c-Cbl, IAP, and AO7, with otherwise diverse structures and functions were linked to ubiquitination (13-16), suggesting a potentially broad and general function for RING fingers in activating Ub ligase activity. One...

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro

“…Cancer-associated proteins identified as being targeted by ubiquitinylation include tumour suppressors such as p53, growth factor receptors, cell cycle regulators and transcription factors (Burger and Seth, 2004). Moreover, there are examples of E3 ligases themselves functioning as oncogenes (Daujat et al, 2001) or tumour suppressor genes, including the breast and ovarian cancer susceptibility gene BRCA1 (Hashizume et al, 2001). HECT/E3 ligases can also function as steroid receptor transcriptional co-activators (White and Parker, 1998), with a proposed functional link to oncogenesis and hormone resistance.…”

BRCA1 gene in breast cancer

“…Subsequently, it was established that that the BRCA1 protein has endogenous ubiquitin ligase activity through its ring domain and that cancer-associating mutations within the ring domain disrupt the BRCA1 ubiquitin ligase activity (Ruffner et al, 2001). The BRCA1-associated ring domain protein BARD1, itself a potential tumor suppressor, also exhibited ubiquitin protein ligase activity; and co-expression of the N-terminal ring domain containing regions of BRCA1 plus BARD1 yielded a synergistic increase in ubiquitin ligase activity (Hashizume et al, 2001). Brzovic et al (2001a,b) have investigated the structural basis for the BRCA1/BARD1 interaction and report that cancer-associated missence mutations of the BRCA1 ring domain do not affect helices required for heterodimerization but instead cause a local perturbation in a region required for the interaction with ubiquitin-conjugating enzymes.…”

Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian Families with high risk of breast cancer

“…31 The BARD1 protein interacts with BRCA1 and both proteins form a complex which possesses a dual E3 ubiquitin ligase activity. 32 The heterodimer BRCA1/BARD1 promotes its own ubiquitination 33 and ubiquitinates RNA pol II subunit A. 34 The interaction of BRCA1 with RNA pol II 11 and DHX9 35 suggested a role for BARD1 in TCR.…”